Warburg and Crabtree Effects in Premalignant Barrett's Esophagus Cell Lines with Active Mitochondria

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Suchorolski, Martin T ^a,b   Paulson, Thomas G ^b   Sanchez, Carissa A ^b   Hockenbery, David ^b   Reid, Brian J ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; DEOXYGLUCOSE; GLUCOSE;

ACIDIFICATION; ARTICLE; BARRETT ESOPHAGUS; CELL LINE; CELL METABOLISM; CONTROLLED STUDY; CRAB TREE EFFECT; ENERGY METABOLISM; EXTRACELLULAR ACIDIFICATION; GENOMIC INSTABILITY; GLYCOLYSIS; HUMAN; HUMAN CELL; METABOLIC RATE; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXYGEN CONSUMPTION; UPREGULATION; WARBURG EFFECT;

2,4-DINITROPHENOL; ACIDS; BARRETT ESOPHAGUS; CELL LINE, TUMOR; DEOXYGLUCOSE; DISEASE PROGRESSION; ENERGY METABOLISM; EXTRACELLULAR SPACE; GENOMIC INSTABILITY; GLYCOLYSIS; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; NEOPLASM STAGING; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRECANCEROUS CONDITIONS; UNCOUPLING AGENTS;

EID: 84874528472     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056884     Document Type: Article

References (42)

1. Warburg O, Wind F, Negelein E, (1927) The Metabolism of Tumors in the Body. The Journal of general physiology 8: 519-530.
2. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
3. Weinhouse S, (1956) On respiratory impairment in cancer cells. Science 124: 267-269.
4. Berridge MV, Herst PM, Tan AS, (2010) Metabolic flexibility and cell hierarchy in metastatic cancer. Mitochondrion 10: 584-588.
5. Zu XL, Guppy M, (2004) Cancer metabolism: facts, fantasy, and fiction. Biochemical and biophysical research communications 313: 459-465.
6. Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, et al. (2011) Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell cycle 10: 4047-4064.
7. Frezza C, Gottlieb E, (2009) Mitochondria in cancer: not just innocent bystanders. Seminars in cancer biology 19: 4-11.
8. Crabtree HG, (1929) Observations on the carbohydrate metabolism of tumours. The Biochemical journal 23: 536-545.
9. Diaz-Ruiz R, Rigoulet M, Devin A, (2011) The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression. Biochimica et biophysica acta 1807: 568-576.
10. Chen Z, Lu W, Garcia-Prieto C, Huang P, (2007) The Warburg effect and its cancer therapeutic implications. Journal of bioenergetics and biomembranes 39: 267-274.
11. Cook MB, Wild CP, Everett SM, Hardie LJ, Bani-Hani KE, et al. (2007) Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 16: 2090-2096.
12. Levine DS, Reid BJ (1992) Endoscopic diagnosis of esophageal neoplasms. In: Boyce GA, Boyce HWJ, editors. Gastrointestinal Endoscopy Clinics of North America. Philadelphia: W. B. Saunders Co. pp. 395-413.
13. Wang KK, Sampliner RE, (2008) Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 103: 788-797.
14. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, et al. (2007) NSAIDs modulate CDKN2A, TP53, and DNA content risk for future esophageal adenocarcinoma. PLoS Med 4: e67.
15. Palanca-Wessels MC, Barrett MT, Galipeau PC, Rohrer KL, Reid BJ, et al. (1998) Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities. Gastroenterology 114: 295-304.
16. Baatar D, Jones MK, Tsugawa K, Pai R, Moon WS, et al. (2002) Esophageal ulceration triggers expression of hypoxia-inducible factor-1 alpha and activates vascular endothelial growth factor gene- Implications for angiogenesis and ulcer healing. American Journal of Pathology 161: 1449-1457.
17. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, et al. (2009) Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery 35: 699-705.
18. Neto CA, Zhuang H, Ghesani N, Alavi A, (2001) Detection of Barrett's esophagus superimposed by esophageal cancer by FDG positron emission tomography. Clinical nuclear medicine 26: 1060.
19. Georgakoudi I, Jacobson BC, Muller MG, Sheets EE, Badizadegan K, et al. (2002) NAD(P)H and collagen as in vivo quantitative fluorescent biomarkers of epithelial precancerous changes. Cancer research 62: 682-687.
20. Griffiths EA, Pritchard SA, McGrath SM, Valentine HR, Price PM, et al. (2007) Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Br J Cancer 96: 1377-1383.
21. Lord RV, Park JM, Wickramasinghe K, DeMeester SR, Oberg S, et al. (2003) Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. The Journal of thoracic and cardiovascular surgery 125: 246-253.
22. Rockett JC, Larkin K, Darnton SJ, Morris AG, Matthews HR, (1997) Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. British journal of cancer 75: 258-263.
23. Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, et al. (2010) Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. Journal of the National Cancer Institute 102: 271-274.
24. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, et al. (2007) Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. American journal of physiology Cell physiology 292: C125-136.
25. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, et al. (2009) LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Molecular cancer therapeutics 8: 626-635.
26. Brandon MC, Ruiz-Pesini E, Mishmar D, Procaccio V, Lott MT, et al. (2009) MITOMASTER: a bioinformatics tool for the analysis of mitochondrial DNA sequences. Hum Mutat 30: 1-6.
27. Chinopoulos C, Gerencser AA, Mandi M, Mathe K, Torocsik B, et al. (2010) Forward operation of adenine nucleotide translocase during F0F1-ATPase reversal: critical role of matrix substrate-level phosphorylation. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24: 2405-2416.
28. Suganuma K, Miwa H, Imai N, Shikami M, Gotou M, et al. (2010) Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylation. Leukemia & lymphoma 51: 2112-2119.
29. Harper ME, Antoniou A, Villalobos-Menuey E, Russo A, Trauger R, et al. (2002) Characterization of a novel metabolic strategy used by drug-resistant tumor cells. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 16: 1550-1557.
30. Diers AR, Broniowska KA, Chang CF, Hogg N, (2012) Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition. The Biochemical journal.
31. Kunz WS, (2003) Different metabolic properties of mitochondrial oxidative phosphorylation in different cell types--important implications for mitochondrial cytopathies. Experimental physiology 88: 149-154.
32. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, et al. (2006) p53 regulates mitochondrial respiration. Science 312: 1650-1653.
33. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, et al. (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120.
34. Younes M, Ertan A, Lechago LV, Somoano J, Lechago J, (1997) Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia. Cancer Epidemiology Biomarkers & Prevention 6: 303-305.
35. Koss K, Harrison RF, Gregory J, Darnton SJ, Anderson MR, et al. (2004) The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. Journal of clinical pathology 57: 1156-1159.
36. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G, (2001) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research 7: 1661-1668.
37. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, et al. (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. Journal of the National Cancer Institute 93: 309-314.
38. Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, et al. (2004) Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. Journal of the National Cancer Institute 96: 946-956.
39. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, et al. (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Molecular and cellular biology 22: 7004-7014.
40. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, et al. (2011) Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature.
41. Chen G, Izzo J, Demizu Y, Wang F, Guha S, et al. (2009) Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol. Antioxidants & redox signaling 11: 1083-1095.
42. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.